ArticleEuropean journal of clinical pharmacology2026
The Scottish medicines in pregnancy programme: supporting the surveillance of medicines use during pregnancy and assessment of associated clinical outcomes.
Article in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evidence on medicines use and safety during pregnancy: pharmacovigilance or pharmacodrowsinesss ?European journal of clinical pharmacology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePharmacological treatment during pregnancy is often necessary but presents challenges due to limited availability of safety data. In response to a UK-wide review of medicine safety, the Scottish Government commissioned the development of a national surveillance infrastructure to monitor medicines use during pregnancy and associated clinical outcomes.
methodsTwo real-world data assets were developed by integrating routinely collected primary and secondary care data: the Scottish Combined Medicines Dataset (SCoMeD) consolidates medicines data, while the Scottish Linked Pregnancy and Baby Dataset (SLiPBD) captures comprehensive data related to pregnancies. Two exemplar case studies were conducted to test the utility of these datasets. First, an audit of anti-seizure medicines (ASM) prescribing 04.2018–03.2025; and second, a retrospective cohort study of pregnancies conceived between 04.2010 and 06.2023, matching ASM exposed to ASM unexposed pregnancies to assess pregnancy, baby, and early childhood outcomes. Study periods were chosen based on data availability.
resultsThe linkage of SCoMeD and SLiPBD enabled national-level surveillance of ASM prescribing trends and in-utero exposures. ASM prescribing surveillance showed an expected decrease in the use of valproate and topiramate among women of childbearing age, reflecting regulatory risk minimisation measures. Observational analyses confirmed valproate-associated teratogenic and developmental risks, whilst supporting the relative safety of lamotrigine and levetiracetam during pregnancy.
conclusionsThis programme demonstrates the value of leveraging nation-wide, whole system data for the surveillance of medicines safety in pregnancy. The linkage of real-world data provides regulatory-relevant evidence to inform guidelines and risk minimisation strategies. Scotland’s integrated medicines infrastructure positions the country as a key contributor in the European pharmacovigilance landscape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.